Fostera™ PCV MH Licensed for Industry-leading 23-week Duration of Immunity Against PCV Combination Vaccine21 August 2014
US - The US Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, which is three weeks longer than any other PCV2 vaccine on the market.
Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2).
“PCVAD continues to be one of the most economically harmful swine diseases. Affected pigs suffer from progressive weight loss, increased mortality and other clinical impacts, which takes a toll on producers’ productivity and profitability,” said Darrell Neuberger, DVM, Pork Technical Services, Zoetis.
“Now, with a vaccine that offers at least 23 weeks of immunity, producers have another tool to help their pigs realize the full market potential with convenience and flexibility.”
Introduced in November 2013, Fostera PCV MH was developed to help protect pigs from PCVAD and enzootic pneumonia caused by M. hyo.
In clinical research studies of the flexible one- and two-dose protocols, Fostera PCV MH has been demonstrated to aid in preventing viremia, lymphoid depletion and colonization of lymphoid tissue caused by PCV2; and as an aid in reducing PCV2 virus shedding and enzootic pneumonia caused by M. hyo.
Unlike other combination vaccines that require field mixing, the one-bottle formulation of Fostera PCV MH allows the convenience of a one-dose program or the flexibility of a two-dose program.
Fostera PCV MH is licensed for administration of pigs three weeks of age or older by a single two mL intramuscular dose or two one mL intramuscular doses spaced two weeks apart.
“We strive to bring solutions to producers and veterinarians through innovative techniques and continued research,” Dr Neuberger said.
“We will continue to invest in our existing products as well as new technology and research to continue that commitment for our customers.”
|ThePigSite News Desk||Read more Zoetis news here|